Download PDF

1. Company Snapshot

1.a. Company Description

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia.


Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Show Full description

1.b. Last Insights on PODD

Insulet Corporation faced negative drivers, including a 38.7% reduction in its stake by Allspring Global Investments Holdings LLC, which may have raised concerns about the company's growth prospects. Although DekaBank Deutsche Girozentrale raised its holdings by 1.0%, and Chicago Partners Investment Group LLC acquired a new position, these moves didn't outweigh the potential negative impact. Moreover, the company's Q3 earnings call revealed rising costs, although Insulet reported strong Omnipod growth and margin expansion. According to Zacks, Insulet was upgraded to a Strong Buy rating, reflecting growing optimism about its earnings prospects.

1.c. Company Highlights

2. Insulet Corporation Delivers Strong Q3 Earnings

Insulet Corporation reported a robust third quarter, with revenues surpassing $700 million, representing a 28% year-over-year growth at constant currency rates and 30% at reported rates. Operating margins expanded 90 basis points year-over-year to 17.1%. The company's earnings per share (EPS) came in at $1.24, beating analyst estimates of $1.13. The strong financial performance was driven by continued demand for Omnipod 5 across Type 1 and Type 2 customers, with U.S. Omnipod revenue growing 25.6% above the high end of the company's guidance range.

Publication Date: Nov -08

📋 Highlights

Business Momentum

The company's U.S. Type 1 market continues to extend its lead, with sequential and year-over-year growth in new customer starts, fueled by ongoing prescriber expansion and the highest number of competitive conversions since late 2023. In U.S. Type 2, Insulet is seeing strong momentum, with new customer starts more than doubling year-over-year and growing sequentially. The international business also delivered robust growth, reflecting increasing global demand and successful execution.

Guidance and Outlook

Insulet expects total Omnipod revenue growth of 27% to 30% and total company growth of 25% to 28% in the fourth quarter. For the full year 2025, the company is raising its total Omnipod revenue growth guidance to 29% to 30% from prior guidance of 25% to 28%. The company also expects a favorable impact of approximately 500 basis points from foreign currency. Analysts estimate next year's revenue growth at 19.3%, which is lower than the current year's growth rate.

Valuation

With a P/E Ratio of 91.41 and an EV/EBITDA ratio of 53.45, Insulet's valuation multiples are high, indicating that the market has already priced in significant growth expectations. The company's ROE of 18.27% and ROIC of 18.09% suggest strong profitability. However, the high valuation multiples may limit the stock's upside potential unless the company continues to deliver strong growth and margin expansion.

3. NewsRoom

Card image cap

Fisher Asset Management LLC Trims Position in Insulet Corporation $PODD

Dec -04

Source: defenseworld.net

Card image cap

Artisan International Small-Mid Fund Q3 2025 Contrarianism Pays Off

Nov -26

Source: seekingalpha.com

Card image cap

Insulet Corporation (PODD) Analyst/Investor Day Transcript

Nov -21

Source: seekingalpha.com

Card image cap

Insulet Outlines Long-Term Strategy to Drive Growth and Value Creation at 2025 Investor Day

Nov -20

Source: businesswire.com

Card image cap

3 Stocks With Upgraded Broker Ratings to Buy for Solid Returns

Nov -20

Source: zacks.com

Card image cap

4 Medical Product Stocks to Watch From a Challenging Industry

Nov -17

Source: zacks.com

Card image cap

Why Insulet (PODD) Might be Well Poised for a Surge

Nov -13

Source: zacks.com

Card image cap

Best Momentum Stocks to Buy for Nov. 13

Nov -13

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (13.72%)

6. Segments

United States Omnipod

Expected Growth: 13.5%

Insulet's Omnipod growth is driven by increasing adoption of tubeless insulin delivery systems, expanding reimbursement coverage, and growing awareness of the benefits of continuous glucose monitoring. Additionally, the company's strategic partnerships, investments in digital health technologies, and geographic expansion into new markets are contributing to the 13.5% growth rate.

International Omnipod

Expected Growth: 14.5%

Insulet's International Omnipod growth is driven by increasing adoption of tubeless insulin delivery systems, expanding global presence, and growing demand for diabetes management solutions. Strong marketing efforts, strategic partnerships, and favorable reimbursement trends also contribute to the 14.5% growth rate.

Drug Delivery

Expected Growth: 12.5%

Insulet Corporation's 12.5% growth in Drug Delivery is driven by increasing adoption of Omnipod insulin management systems, expansion into new markets, and growing demand for tubeless and wireless insulin delivery solutions. Additionally, strategic partnerships and investments in research and development are contributing to the company's growth momentum.

7. Detailed Products

Omnipod Insulin Management System

A wearable, tubeless insulin pump that provides continuous insulin delivery and insulin bolus dosing for people with diabetes.

Omnipod DASH System

A next-generation insulin management system that combines a wearable insulin pump with a mobile app and a Contour Next Link 2.4 meter.

Omnipod 5 System

An automated insulin delivery system that integrates with a continuous glucose monitor and a mobile app to provide personalized insulin dosing recommendations.

8. Insulet Corporation's Porter Forces

Forces Ranking

Threat Of Substitutes

Insulet Corporation's Omnipod System is a unique product with limited substitutes, but patients may opt for traditional insulin pumps or multiple daily injections as alternatives.

Bargaining Power Of Customers

Insulet Corporation's customers, primarily patients with diabetes, have limited bargaining power due to the unique nature of the Omnipod System and the company's strong brand reputation.

Bargaining Power Of Suppliers

Insulet Corporation has a diversified supplier base, reducing dependence on individual suppliers and limiting their bargaining power.

Threat Of New Entrants

The medical device industry, particularly the insulin pump market, has high barriers to entry, including regulatory hurdles and significant R&D investments, making it challenging for new entrants to compete with Insulet Corporation.

Intensity Of Rivalry

The insulin pump market is moderately competitive, with a few established players, including Medtronic and Tandem Diabetes Care, but Insulet Corporation's unique product offerings and strong brand reputation help to differentiate it from competitors.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 65.95%
Debt Cost 3.95%
Equity Weight 34.05%
Equity Cost 8.88%
WACC 5.63%
Leverage 193.71%

11. Quality Control: Insulet Corporation passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Insulet

A-Score: 5.1/10

Value: 0.2

Growth: 9.6

Quality: 6.5

Yield: 0.0

Momentum: 8.0

Volatility: 6.3

1-Year Total Return ->

View Full Report
Stock-Card
Inari Medical

A-Score: 5.1/10

Value: 6.0

Growth: 8.0

Quality: 4.5

Yield: 0.0

Momentum: 10.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
CONMED

A-Score: 4.8/10

Value: 6.4

Growth: 6.4

Quality: 5.9

Yield: 3.0

Momentum: 2.0

Volatility: 5.0

1-Year Total Return ->

View Full Report
Stock-Card
iRhythm Technologies

A-Score: 4.6/10

Value: 4.2

Growth: 6.1

Quality: 3.1

Yield: 0.0

Momentum: 10.0

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
Bio-Rad

A-Score: 3.8/10

Value: 6.4

Growth: 2.3

Quality: 5.9

Yield: 0.0

Momentum: 3.0

Volatility: 5.0

1-Year Total Return ->

View Full Report
Stock-Card
Integra LifeSciences

A-Score: 3.3/10

Value: 9.0

Growth: 2.3

Quality: 3.5

Yield: 0.0

Momentum: 2.0

Volatility: 2.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

304.49$

Current Price

304.49$

Potential

-0.00%

Expected Cash-Flows